Background
Due to the lack of biomarkers for post treatment control (PTC), analytical treatment interruption (ATI) remains the ‘gold standard’ endpoint in HIV cure trials. However, CD8+ T cell responses are thought to be critical for spontaneous control of HIV but findings supporting their role in PTC from smaller cohort studies have been mixed. We hypothesized that pre-ATI HIV-specific CD8+ T cell proliferation and interferon-γ (IFNγ) response were associated with delayed viral rebound.
Methods
We pooled data from six different HIV cure trials including people living with HIV receiving ART alone or combined with latency reversing agents, TLR9 agonists, or broadly neutralizing antibodies. Pre-ATI blood samples were analyzed by IFNγ ELISpot and lymphocyte proliferation assay (LPA). Participants were stratified by time to detectable viremia (>50 copies/mL) and time to loss of virological control (two consecutive measurements of >1000 copies/mL), using a 28-day threshold (median time to loss of control). Responses were compared using Mann-Whitney U tests. Kaplan-Meier and Cox proportional hazards regression analyses assessed time to detectable viremia and loss of control based on high/low HIV-specific ELISpot and LPA responses stratified by median.
Results
Among the 91 participants (90% male, median age 45), only 14.3% had undetectable viremia 28 days post-ATI. ELISpot or LPA responses were not associated with time to detectable viremia (all p>0.1). Compared to participants who had lost control at day 28, participants with viral control (n=46) had significantly higher GAG-specific IFNγ ELISpot (215 vs. 45 SFC/10⁶ PBMCs, p=0.017) and greater CD8+ T cell proliferation (0.47% vs. 0.17%, p=0.034) responses pre-ATI. Similarly, Kaplan-Meier plots showed longer time to loss of control among individuals with high GAG-specific IFNγ ELISpot or CD8+ T cell proliferation (28 vs. 21 days, p=0.002 and p=0.039, resp.) responses. In a multi-variate analysis, high GAG-specific IFNγ ELISpot responses trended towards being more independently associated with reduced risk of losing control (HR 0.54, 95% CI 0.29-1.02, p=0.058) than GAG-specific CD8+ proliferation (HR 0.87, 95% CI 0.47-1.62, p=0.668).
Conclusions
Our findings indicate that high GAG-specific IFNγ ELISpot and CD8+ T cell proliferation responses prior to ATI were associated with prolonged virological control but not time to detectable viremia. These findings support a role for CD8+ T cells in sustaining virological control after stopping ART.